Ten samples from 76 patients (13.2%) were positive by real-time polymerase chain 26 reaction (PCR). In this study, we concluded that, LDLT recipients are at high risk of 27 HCMV infection (13.2%) and the most suitable method for HCMV detection was 28 PCR. 29
42
The great seroprevalence and early acquisition of the virus have been associated 43 with lower socioeconomic circumstances, developing countries and over crowded 44 populations (3). HCMV infects 60%-100% of humans, with primary HCMV infection 45 occurring most commonly during the first two decades of life. In immunocompetent 46
individuals, the infected individuals are mostly asymptomatic or may present with a 47 benign febrile infectious mononucleosis-like illness (4) . HCMV infection occur in the 48 majority of solid organ transplant patients, primarily in the first months when 49
immunosuppression is most intense, HCMV disease incidence ranges from 10% to 50 50% (4).
51
Liver transplant recipients are at a higher risk of HCMV infection, especially 52 those who did not have HCMV infection until they receive a latently infected organ 53 from a HCMV-seropositive donor (HCMV D+/R-mismatch). The risk of progression 54
into HCMV disease is magnified by the intense immunosuppression required to avoid 55 or to treat allograft rejection (5) . The clinical impact of HCMV disease after liver 56 transplantation can be classified into: (1) an acute infection with clinical signs known 57 as direct effects (fever, mononucleosis, and invasive organ disease); and (2) a broad 58 range of immunomodulatory and vascular effects, referred to as indirect effects (6) .
60
The aim of this study was to detect the incidence of HCMV infections in living-61 Prevalence of positive HCMV in studied group I= 13.2% (Table 6) . 151
Clinical data of HCMV in studied group I (n=76). Gastroenteritis, hepatitis 152
and fever showed significant differences between positive cases versus control 153 subjects (p=0.033, 0.003, 0.001 respectively). Pneumonitis did not differ significantly 154 between positive cases and control subjects (Table 7) . 155
Clinical indications did not show significant differences between patients with 156 positive HCMV infection versus those with negative HCMV infection and versus 157 control subjects (p>0.05) ( Table 8) . 158
The relation between HCMV infection and laboratory data was increased 159 serum bilirubin (total and direct) and GGT showed high significance differences 160 between group I and control group (group II) (p=0.002, 0.001, 0.009 respectively), 161
increased ALP and glucose showed marginally significant differences (p=0.093, 162 0.071 respectively), increased CRP showed a significant difference (p=0.038). Mild 163 reduction of hemoglobin concentration and mild elevation of INR showed marginally 164 significance (p=0.0503, 0.066 respectively) ( Table 9) . 165
The relationship of post-transplant complications with active HCMV in-group 166 I (n=76) versus control group. Recurrent HCV had higher incidence of HCMV 167 infection (40.0% versus 12.1% in positive versus negative HCMV, p=0.046). Casespancytopenia (Table 10) on liver transplantation and hepatitis C. Liver Transpl.; 9:S1-S9. 340 
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